Stock Analysis on Net
Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Total Asset Turnover 
since 2005

Microsoft Excel

Calculation

Gilead Sciences Inc., total asset turnover, long-term trends, calculation

Microsoft Excel
Total asset turnover = Product sales1 ÷ Total assets1
Dec 31, 2024 0.48 = 28,610 ÷ 58,995
Dec 31, 2023 0.43 = 26,934 ÷ 62,125
Dec 31, 2022 0.43 = 26,982 ÷ 63,171
Dec 31, 2021 0.40 = 27,008 ÷ 67,952
Dec 31, 2020 0.36 = 24,355 ÷ 68,407
Dec 31, 2019 0.36 = 22,119 ÷ 61,627
Dec 31, 2018 0.34 = 21,677 ÷ 63,675
Dec 31, 2017 0.37 = 25,662 ÷ 70,283
Dec 31, 2016 0.53 = 29,953 ÷ 56,977
Dec 31, 2015 0.62 = 32,151 ÷ 51,839
Dec 31, 2014 0.71 = 24,474 ÷ 34,664
Dec 31, 2013 0.48 = 10,804 ÷ 22,497
Dec 31, 2012 0.44 = 9,398 ÷ 21,240
Dec 31, 2011 0.47 = 8,102 ÷ 17,303
Dec 31, 2010 0.64 = 7,390 ÷ 11,593
Dec 31, 2009 0.67 = 6,469 ÷ 9,699
Dec 31, 2008 0.72 = 5,085 ÷ 7,019
Dec 31, 2007 0.64 = 3,733 ÷ 5,835
Dec 31, 2006 0.63 = 2,588 ÷ 4,086
Dec 31, 2005 0.48 = 1,809 ÷ 3,765

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in millions

The financial data reflects notable trends in key performance metrics over the observed period. Product sales showed a consistent upward trajectory from 2005 through 2014, increasing from $1,809 million to a peak of $32,151 million. Following this peak, sales experienced a gradual decline until 2018, dropping to $21,677 million, before modestly recovering and stabilizing around the $27 billion mark in the most recent years.

Total assets demonstrated steady growth from $3,765 million in 2005 to a high of $70,283 million in 2017. However, from 2017 onwards, assets contracted progressively, reaching $58,995 million by 2024. This decline suggests a period of asset base optimization or divestitures during the latter years.

Total asset turnover exhibited volatility throughout the timeline. The ratio improved initially, reaching its highest point of 0.72 in 2008, indicating effective utilization of assets during that period. Subsequently, there was a downward trend, with turnover decreasing to a low of 0.34 in 2018, signaling a decline in asset efficiency relative to sales. More recently, a modest recovery has been observed, with the ratio increasing to 0.48 by 2024, suggesting improved performance in asset utilization.

Product Sales
Grew significantly until 2014, nearly doubling from 2005. Declined over four years post-2014, followed by stabilization around $27 billion.
Total Assets
Steadily increased to 2017 peak, then decreased gradually up to 2024, indicating potential restructuring or asset optimization.
Total Asset Turnover
Peaked in 2008, followed by a decline to 2018, and partial recovery afterward, reflecting changes in asset efficiency in relation to sales.

Overall, the data suggest that the company underwent a growth phase up to the mid-2010s, with both sales and assets expanding substantially. Following this, a period of contraction and efficiency challenges emerged, as indicated by declining asset turnover and total assets. The recent stabilization in sales and improvement in asset turnover imply efforts toward operational optimization and better asset management.

Comparison to Competitors

Gilead Sciences Inc., total asset turnover, long-term trends, comparison to competitors

Microsoft Excel
Gilead Sciences Inc. AbbVie Inc. Amgen Inc. Bristol-Myers Squibb Co. Danaher Corp. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. Pfizer Inc. Regeneron Pharmaceuticals Inc. Thermo Fisher Scientific Inc. Vertex Pharmaceuticals Inc.
Dec 31, 2024 0.48 0.42 0.35 0.52 0.31 0.57 0.49 0.55 0.30 0.38 0.44 0.49
Dec 31, 2023 0.43 0.40 0.28 0.47 0.28 0.53 0.51 0.56 0.26 0.40 0.43 0.43
Dec 31, 2022 0.43 0.42 0.38 0.48 0.37 0.58 0.51 0.54 0.51 0.42 0.46 0.49
Dec 31, 2021 0.40 0.38 0.40 0.42 0.35 0.58 0.52 0.46 0.45 0.63 0.41 0.56
Dec 31, 2020 0.36 0.30 0.39 0.36 0.29 0.53 0.47 0.52 0.28 0.50 0.47 0.53
Dec 31, 2019 0.36 0.37 0.37 0.20 0.29 0.57 0.52 0.55 0.31 0.53 0.44 0.50
Dec 31, 2018 0.34 0.55 0.34 0.64 0.42 0.56 0.53 0.51 0.34 0.57 0.43 0.49
Dec 31, 2017 0.37 0.40 0.27 0.62 0.39 0.51 0.49 0.46 0.31 0.67 0.37 0.70
Dec 31, 2016 0.53 0.39 0.28 0.58 0.37 0.55 0.51 0.42 0.31 0.70 0.40 0.59
Dec 31, 2015 0.62 0.43 0.29 0.52 0.43 0.56 0.53 0.39 0.29 0.73 0.41 0.41
Dec 31, 2014 0.71 0.72 0.28 0.47 0.54 0.53 0.57 0.43 0.29 0.73 0.39 0.25
Dec 31, 2013 0.48 0.64 0.28 0.42 0.55 0.66 0.54 0.42 0.30 0.71 0.41 0.52
Dec 31, 2012 0.44 0.68 0.31 0.49 0.55 0.66 0.55 0.45 0.32 0.66 0.46 0.55
Dec 31, 2011 0.47 — 0.31 0.64 0.54 0.72 0.57 0.46 0.36 0.34 0.44 0.64
Dec 31, 2010 0.64 — 0.34 0.63 0.59 0.74 0.60 0.43 0.35 0.42 0.51 0.08
Dec 31, 2009 0.67 — 0.36 0.61 0.57 0.80 0.65 0.24 0.23 0.51 0.47 0.05
Dec 31, 2008 0.72 — 0.40 0.70 0.73 0.70 0.75 0.51 0.43 0.36 0.50 0.18
Dec 31, 2007 0.64 — 0.41 0.74 0.63 0.70 0.75 0.50 0.42 0.13 0.46 0.33
Dec 31, 2006 0.63 — 0.41 0.70 0.75 0.71 0.76 0.51 0.42 0.11 0.18 0.23
Dec 31, 2005 0.48 — 0.41 0.68 0.87 0.60 0.87 0.49 0.44 0.16 0.62 0.29

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Gilead Sciences Inc., total asset turnover, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel
Gilead Sciences Inc. Pharmaceuticals, Biotechnology & Life Sciences
Dec 31, 2024 0.48 0.43
Dec 31, 2023 0.43 0.40
Dec 31, 2022 0.43 0.47
Dec 31, 2021 0.40 0.45
Dec 31, 2020 0.36 0.39
Dec 31, 2019 0.36 0.39
Dec 31, 2018 0.34 0.45
Dec 31, 2017 0.37 0.40
Dec 31, 2016 0.53 0.41
Dec 31, 2015 0.62 0.42
Dec 31, 2014 0.71 0.44
Dec 31, 2013 0.48 0.43
Dec 31, 2012 0.44 0.45
Dec 31, 2011 0.47 0.47
Dec 31, 2010 0.64 0.47
Dec 31, 2009 0.67 0.39
Dec 31, 2008 0.72 0.57
Dec 31, 2007 0.64 0.56
Dec 31, 2006 0.63 0.54
Dec 31, 2005 0.48 0.57

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

Comparison to Industry (Health Care)

Gilead Sciences Inc., total asset turnover, long-term trends, comparison to industry (health care)

Microsoft Excel
Gilead Sciences Inc. Health Care
Dec 31, 2024 0.48 0.75
Dec 31, 2023 0.43 0.73
Dec 31, 2022 0.43 0.75
Dec 31, 2021 0.40 0.70
Dec 31, 2020 0.36 0.64
Dec 31, 2019 0.36 0.65
Dec 31, 2018 0.34 0.68
Dec 31, 2017 0.37 0.66
Dec 31, 2016 0.53 0.67
Dec 31, 2015 0.62 0.64
Dec 31, 2014 0.71 0.69
Dec 31, 2013 0.48 0.67
Dec 31, 2012 0.44 0.67
Dec 31, 2011 0.47 0.69
Dec 31, 2010 0.64 0.68
Dec 31, 2009 0.67 0.63
Dec 31, 2008 0.72 0.80
Dec 31, 2007 0.64 0.77
Dec 31, 2006 0.63 0.74
Dec 31, 2005 0.48 0.72

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).